[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.187.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 11, 2002

Risks of Postmenopausal Hormone Replacement

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(22):2821. doi:10.1001/jama.288.22.2821-JLT1211-1-7

To the Editor: Although the WHI investigators first became aware of the possibility of cardiovascular harmful effects of the progestin-estrogen combination in late 1999, the data and safety monitoring board (DSMB) did not stop the trial then.1 This decision seems questionable in light of other important double-blind placebo-controlled trials published in 1998-1999, such as HERS,2 PEPI mammography results,3 and SPAF,4 all of which found evidence of potential harmful cardiovascular and premalignant effects of combined HRT.

First Page Preview View Large
First page PDF preview
First page PDF preview
×